CIRSE Congress 2025 - Hisotripsy using the HistoSonics Investigational System was a successful and safe treatment option for primary solid renal tumours.

Prof Tze Min Wah (Leeds Teaching Hospitals NHS Trust, Leeds, UK) joins us to discuss findings from the first report of the technical success and safety of the HistoSonics Investigational System for the treatment of primary solid renal tumors. The prospective, multi-center, single-arm pilot trial enrolled patients with primary solid renal tumours, and technical success was determined by post-hisotripsy imaging. The study aimed to determine the safety and efficacy of the HistoSonics system for the treatment of small renal cancers.

Findings showed a 90% early efficacy rate at 30 days.

Interview Questions:

1. What are the current unmet needs in the treatment of primary solid renal tumours, and what is the importance behind the trial?
2. Could you tell us about the unique features of the HistoSonics Investigational System?
3. What was the study design and patient population?
4. What were the key findings?
5. What are the take-home messages for practice?
6. What further research is needed in this area?

Recorded virtually from Leeds, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent

Support: This is an independent interview produced by Radcliffe CVRM.